|
業務類別
|
Medical Devices |
|
業務概覽
|
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe. |
| 公司地址
| 566 Queensbury Avenue, Queensbury, NY, USA, 12804 |
| 電話號碼
| +1 518 743-8892 |
| 傳真號碼
| +1 212 489-2102 |
| 公司網頁
| https://www.delcath.com |
| 員工數量
| 156 |
| Dr. Martha S. Rook, PhD |
Chief Operating Officer |
美元 460.83K |
02/04/2026 |
| Ms. Sandra Pennell |
Chief Financial Officer and Principal Accounting Officer |
-- |
02/04/2026 |
| Mr. David L. Hoffman |
General Counsel, Chief Compliance Officer and Corporate Secretary |
-- |
02/04/2026 |
| Mr. Gerard J. Michel |
Director and Chief Executive Officer |
美元 635.71K |
02/04/2026 |
| Mr. Kevin Muir |
General Manager, Interventional Oncology |
-- |
02/04/2026 |
| Dr. Vojislav Vukovic, M.D.,PhD |
Chief Medical Officer |
美元 488.00K |
02/04/2026 |
|
|
| Ms. Elizabeth A. Czerepak |
Independent Director |
02/04/2026 |
| Dr. Bridget Martell, M.A. |
Independent Director |
02/04/2026 |
| Mr. Steven Salamon |
Independent Director |
02/04/2026 |
| Dr. Gilad Aharon, PhD |
Independent Director |
02/04/2026 |
| Mr. Gerard J. Michel |
Director and Chief Executive Officer |
02/04/2026 |
| Mr. John Richard Sylvester |
Chairman |
02/04/2026 |
|
|
|
|
